Masterclass in Clinical Oncology - Autumn edition

Course Leadership

Masterclass Chairs: J. But Hadžic, SI - T. Cufer, SI
Host Chair: V. Guarneri, IT
Scientific Supervisor: R. Audisio, SE/IT

Aims, objectives and teaching format

The ESO Masterclass is a full immersion, clinical oriented event designed for medical and clinical oncologists with 3-4 years experience in oncology who would like to receive further training on the treatment of tumours from a multidisciplinary point of view. The programme exposes participants to a full spectrum of issues in clinical oncology and to practice-oriented training.
The Masterclass is organized into:

• Plenary lectures on state-of-the-art clinical treatments with reference to clinical guidelines given by renowned international faculty.
• Interactive workshops
• Clinical case presentations/tumour board simulation where each participant presents and discusses their case with an international faculty of top experts in each tumour type.

The Masterclass is divided into two educational parts:

1. Pre-recorded online lectures - from 19 September 2025
2. In-person event - 24-28 October 2025

The online lectures are released before the in-person event to give each participant the opportunity to prepare themselves in their own time and at their own pace.

The in-person event is held in the style of a 3-and-half-day ‘retreat’, giving participants the opportunity to begin building an international oncology network as well as the chance to interact with renowned faculty in an informal environment over a number of days.

The Masterclass is held entirely in English and fluency in English is necessary for admission.

The ESO Masterclass in Clinical Oncology: Autumn edition is a closed event for selected participants only.

LANGUAGE

The Masterclass will be held in English and translation will not be provided.

FEE

The Masterclass will take place in San Servolo (Venice), Italy.

If selected, a registration fee of 250 EUR will be requested in order to confirm your participation in this event.

The fee covers:

• Access to the course and its educational resources
• Accommodation for 4 nights 
• Meals according to the programme

The fee does not cover travel costs, these should be organized and paid by the participant.

Participants who are ESO College members at the time of application will receive a 50% discount.

The registration fee for this event is a small contribution towards the cost for organising it, therefore it will not be refunded if a participant withdraws or is unable to attend, for whatever reason.

ACCREDITATION

Participants will be issued a certificate of attendance (minimum attendance: 75% of the online part + 100% of the in-person event). An online evaluation questionnaire and learning assessment test will need to be completed for both parts in order to get the certificate that will be sent by email.

The Accreditation Council of Oncology in Europe (ACOE) has awarded this course 46.5 CME credits.

ESO COLLEGE MEMBERSHIP

Being selected to take part in this course is one of the ESO activities that gives participants eligibility to enrol in ESO’s College. The course also enables members of the College to earn credits and therefore access more membership benefits. Full and active participation in the course earns participants 30 ESO College credits.

Visit www.ESCO.org for more information on how to join the College.

ORGANISING SECRETARIAT

Sonia Bulgarelli
European School of Oncology
ph +39 337 1061207
e-mail: sbulgarelli@eso.net

Elena Fiore
European School of Oncology
ph + 39 335 169 4160
e-mail: efiore@eso.net

Dolores Knupfer
European School of Oncology
ph +41 91 820 09 50
e-mail: dknupfer@eso.net

 APPLICATIONS CLOSED

ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY

60 PARTICIPANTS WILL BE SELECTED.

IDEAL PROFILE OF THE MASTERCLASS CANDIDATE

• Aged up to 40 years
• 2-3 years’ experience in clinical work with cancer patients
• Involvement in scientific activities and clinical trials
• Fluency in English
• From ESO’s geographical reach: Europe, Mediterranean countries and Latin America

Priority will also be given to candidates who:

• Have previously participated in ESO’s Basic Principles of Oncology course.
• Are members of ESO’s College.

HOW TO APPLY

Interested oncologists should apply online (at the top of this page).

The application process involves completing an online questionnaire, where you will provide details about:

• Your work experience and training
• Your research experience and publications
• Your motivation and personal commitment to participating in this activity

During the application, you will also need to upload the following documents in PDF format:

• Recommendation letter: A letter from your head of department or mentor, written on official hospital letterhead and signed.
• Curriculum Vitae (CV)
• Clinical case: Please use the provided template available below.

SELECTION PROCESS

Applications are evaluated through a two-step process:

1. Automated Scoring: Some responses are assessed using a predefined scoring system to ensure fairness and consistency. Points are assigned based on your answers.
2. Committee Evaluation: Other sections, including your qualitative responses, are reviewed and scored by our selection committee.

This type of evaluation ensures a transparent and unbiased selection of top candidates for participation in this activity.

Before you start completing the online application form, please be sure you have all the requested files (CV, Recommendation letter, and Clinical Case template) ready to be uploaded to the system. Online applications will not be considered unless all the files are uploaded.

TEMPLATE

• Download your Clinical case template HERE

CLINICAL CASE PRESENTATION

During the in-person event all participants will have the chance to present a clinical case as a clinical grandround discussion to the faculty and participants.

A template giving details of the clinical case you would like to present should be submitted with your application. Please provide a straightforward case found in your daily clinical practice - no uncommon or extremely rare cases. You should include

• Diagnostic considerations
• Treatment
• Results, follow-up
• At least three questions proposed for discussion with the faculty

If you are selected for the Masterclass, you will be asked to prepare a PowerPoint presentation of your case (max 10 slides). If we receive too many cases from one tumour group, we may ask you to change the case topic you submitted during your application. We kindly ask you to let us know your 2^nd choice topic if your first choice cannot be accommodated.

Riccardo A. Audisio, Institute of Clinical Sciences - Sahlgrenska University Hospital, Dept. of Surgery, Göteborg, SE
Giulia Baciarello, San Camillo-Forlanini Hospitals, Medical Oncology Dpt., Rome, IT
Luca Bertolaccini, IEO, Istituto Europeo di Oncologia IRCCS, Thoracic Surgery Dpt., Milano, IT
Luca Bertolaccini, IEO, Istituto Europeo di Oncologia IRCCS, Thoracic Surgery Dpt., Milano, IT
Joerg Beyer, University Hospital of Bern, Oncology and Medicine Dept., Bern, CH
Eduard Alexandru Bonci, Champalimaud Research and Clinical Centre, Breast Unit, Lisbon, PT
Giovanni Boniolo, University of Ferrara, Dept. of Neuroscience and Rehabilitation, Ferrara, IT
Jasna But Hadžic, Faculty of Medicine - University of Ljubljana, Dept. of Oncology, Ljubljana, SI
Fiorella Calabrese, University of Padova, Anatomo Pathology Dpt., Padova, IT
Antonio Calles, University General Hospital Gregorio Maranon, Dept. of Thoracic Oncology, Madrid, ES
Felipe A. Calvo Manuel, Clinica Universidad de Navarra, Dept. of Radiation Oncology, Madrid, ES
Fatima Cardoso, Champalimaud Clinical Center, Breast Unit, Lisbon, PT
Paolo Giovanni Casali, National Cancer Institute - IRCCS Foundation, Medical Oncology Unit 2, Milan, IT
Franco Cavalli, Foundation for the Institute of Oncology Research (IOR), Presidenza, Bellinzona, CH
Ian Chau, Royal Marsden Hospital, Department of Medicine, Sutton, Surrey, UK
Ilaria Colombo, Oncology Institute of Southern Switzerland, EOC, Oncology Dpt., Bellinzona, CH
Nicoletta Colombo, Istituto Europeo di Oncologia, Programma Ginecologia Oncologica, Milano, IT
Carmen Criscitiello, European Institute of Oncology, New Drugs and Early Drug Development for Innovative Therapies Dpt., Milan, IT
Tanja Cufer, University of Ljubljana, Medical Faculty, Ljubljana, SI
Giuseppe Curigliano, European Institute of Oncology / University of Milan, New Drugs for Innovative Therapies Division, Milano, IT
Alessandra Curioni-Fontecedro, Freiburger Spital, HFR Kantonsspital Freiburg, Department of Oncology, Freiburg, CH
Sara De Dosso, Oncology Institute of Southern Switzerland (IOSI), Medical Oncology Dpt., Bellinzona, CH
Johan De Munter, University Hospital Ghent, Oncology Dpt., Ghent, BE
Francesca Del Bufalo, IRCCS Peadiatric Hospital Bambino Gesù, Cellular and Genic Therapy Dpt., Roma, IT
Andre D'Hoore, UZ Gasthuisberg, Dept. of Surgery, Leuven, BE
Antonio Di Meglio, Gustave Roussy Institute, Medical Oncology Dpt., Villejuif, FR
Maria Vittoria Dieci, Istituto Oncologico Veneto, Dept. of Oncology 2, Padova, IT
Rodrigo Dienstmann, Vall d’Hebron Institute of Oncology, Molecular Therapeutic Research Unit, Barcelona, ES
Andreas Dietz, University Hospital Leipzig, ENT Dpt., Leipzig, DE
Michel Ducreux, Institute Gustave Roussy, Oncology, Villejuif, FR
Alexandru Eniu, Riviera-Chablais Hospital, Medical Oncology Dpt., Rennaz, CH
Ambrogio Fassina, University of Padova, Pathology Anatomy Dpt., Padova, IT
Andrea Ferrari, Fondazione IRCCS Istituto Nazionale dei Tumori, Div. di Oncologia Pediatrica, Milano, IT
Karim Fizazi, Gustave Roussy Institute, Cancer Medicine Dept., Villejuif, FR
Tania Fleitas Kanonnikoff, Hospital Clinico Universitario de Valencia, Clinical Oncology Dpt., Valencia, ES
Ronan Flippot, Gustave Roussy Institute of Oncology, Urology Dpt., Villejuif, FR
Andrea Gallina, EOC - Ente Ospedaliero Cantonale, Urology Dpt., Bellinzona, CH
Andrea Gallina, EOC - Ente Ospedaliero Cantonale, Urology Dpt., Bellinzona, CH
Fady B. Geara, Cleveland Clinic Abu Dhabi, Dept. of Radiation Oncology, Abu Dhabi, AE
Patrizia Giannatempo, Fondazione IRCCS Istituto Tumori, Medical Oncology Dpt., Milano, IT
Juan Francisco Grau Bejar, Vall d´Hebron University Hospital, Gynaecological Cancer Dpt., Barcelona, ES
Alessandro Gronchi, National Cancer Institute - IRCCS Foundation, Sarcomas Surgery Unit, Milano, IT
Valentina Guarneri, University of Padova, DiSCOG, Padova, IT
Elena Guerini Rocco, European Institute of Oncology IRCCS, Division of Pathology, Milan, IT
Fleur Helewaut, University Ghent, Faculty of Medicine and Health Sciences for the Clinical Skills Training Centre, Ghent, BE
Barbara Alicja Jereczek-Fossa, European Institute of Oncology, Dept. of Radiotherapy, Milano, IT
Fatjona Kraja, Mother Teresa University Hospital, Oncology Dept., Tirana, AL
Fatjona Kraja, Mother Teresa University Hospital, Oncology Dept., Tirana, AL
Beata Laki, Medical School, University of Pécs, Dept. of Behavioural Sciences, Pécs, HU
Angela Lamarca, Fundación Jiménez Díaz University Hospital, Department of Oncology – OncoHealth Institute, Madrid, ES
An Lievrouw, Ghent University Hospital, Cancer Center Dpt., Ghent, BE
Ainhoa Madariaga, Hospital Universitario 12 de Octubre, Medical Oncology Dpt., Madrid, ES
Umberto Malapelle, University of Naples Federico II, Dpt. of Public Health, Naples, IT
Olivier Michielin, Geneve University Hospital, Medical Oncology Dpt., Geneve, CH
Loredana Mrak, University Clinic Golnik, Medical Oncology Dept., Golnik, SI
Kristel Mulders, Jessa Hospital, Onco-sexology and Cancer Plan Dpt., Hasselt, BE
Ernest Nadal, Institut Català  d'Oncologia, Medical Oncology Department, L'Hospitalet (Barcelona), ES
Jarushka Naidoo, Waterford Regional Hospital, Medical Oncology Dpt., Waterford, IE
Demetris Papamichael, Bank of Cyprus Oncology Centre, Medical Oncology Dpt., Nicosia, CY
Demetris Papamichael, Bank of Cyprus Oncology Centre, Medical Oncology Dpt., Nicosia, CY
Philip Poortmans, Iridium Netwerk & University of Antwerp, Dept. of Radiation Oncology, Wilrijk, BE
Eleonora Petra Preti, IEO - European Institute of Oncology, Gynaecological Cancer Dpt., Milan, IT
Giancarlo Pruneri, National Cancer Institute, IRCCS Foundation, Pathology Dpt., Milano, IT
Amanda Psyrri, Attikon University Hospital, Medical Oncology Dept., Chaidari, GR
Miroslawa Puskulluoglu, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków Branch, Dept. of Clinical Oncology, Krakow, PL
Sara Ramella, University Campus Bio-Medico, Radiotherapy Dpt., Roma, IT
Isabelle Ray-Coquard, Léon Bérard Center, Dept. of Medical Oncology, Lyon, FR
Christian Rolfo, The Arthur G. James Comprehensive Cancer Center, Division of Medical Oncology, Columbus, OH, US
Marzia Salgarello, Policlinico Gemelli, Recostructive Surgery Dpt., Rome, IT
Andrea Sartore-bianchi, Niguarda Hospital, Division of Clinical Research and Innovation, Milano, IT
Manuela Schmidinger, Medical University of Vienna, Department of Urology and Comprehensive Cancer Center, Vienna, AT
Uta Schmidt-strassburger, Ulm University, Learning and Teaching, Medical Faculty, Ulm, DE
Joachim Schuz, AIRC - International Agency for Research on Cancer, Environment and Lifestyle Epidemiology Branch, Lyon, FR
Cristiana Sessa, Istituto Oncologico della Svizzera Italiana, Gynaecology Dpt., Bellinzona, CH
Thomas Seufferlein, Ulm University Hospital, Dept. of Internal Medicine I, Ulm, DE
Alexander Siebenhüner, Kantonsspital Schaffhausen, Oncology Dpt., Schaffhausen, CH
Gaya Spolverato, Azienda Ospedale Università di Padova, Surgery - Gastrointestinal Cancers Dpt., Padova, IT
Alina Sturdza, Comprehensive Cancer Center, Medical University of Vienna, Dept. of Radiation Oncology, Wien, AT
Ian Tannock, Toronto, CA
Roberto Tozzi, University of Padova, Woman and Child's Health Dept., Padova, IT
Annalisa Trama, National Cancer Institute - IRCCS Foundation, ., Milano, IT
Eric Van Cutsem, University Hospital Leuven, Digestive Oncology Dept., Leuven, BE
Bruno Vincenzi, University Campus Bio-Medico, Medical Oncology Dpt., Rome, IT
Marco Vitellaro, Fondazione IRCCS Istituto Nazionale dei Tumori, Surgical Oncology Dpt., Milano, IT
Ursula Vogl, Cantonal Hospital of Southern Switzerland (EOC), IOSI - Oncology Institute of Southern Switzerland, Bellinzona, CH